Authors:
MULLER G
WINTERSTEIN E
HEINRICHS C
SCHOBESS R
MOBIUS D
HOFMANN K
DREGER B
BENDEROMAY R
BEER HJ
Citation: G. Muller et al., PREVIOUSLY TREATED PATIENTS TREATED WITH A DOUBLE VIRAL INACTIVATED FACTOR-VIII CONCENTRATE - A 6-MONTH PHARMACOVIGILANCE STUDY, Thrombosis and haemostasis, 1997, pp. 229-229
Authors:
SCHOBESS R
EXADAKTYLOS P
REISS T
LAUTENSCHLAGER C
Citation: R. Schobess et al., CHANGES IN HEMOSTATIC AND FIBRINOLYTIC PARAMETERS IN CHILDREN WITH ALL RECEIVING L-ASPARAGINASE-(L-ASE) THERAPY, Thrombosis and haemostasis, 1997, pp. 514-514
Authors:
ASCHKA I
AUMANN V
BERGMANN F
BUDDE U
EBERL W
ECKHOFDONOVAN S
KREY S
NOWAKGOTTL U
SCHOBESS R
SUTOR AH
WENDISCH J
SCHNEPPENHEIM R
Citation: I. Aschka et al., PREVALENCE OF FACTOR-V LEIDEN IN CHILDREN WITH THROMBOEMBOLISM, European journal of pediatrics, 155(12), 1996, pp. 1009-1014
Authors:
EXADAKTYLOS P
REISS T
SCHOBESS R
HOMMANN M
HOHNE S
BECK A
Citation: P. Exadaktylos et al., THE ACUTE HEPATOTOXICITY OF INTERMEDIATE- DOSE MTX IN CHILDREN WITH ACUTE-LEUKEMIA AND NON-HODGKIN-LYMPHOMA, Klinische Padiatrie, 206(4), 1994, pp. 315-318